Toll-like receptor 2: therapeutic target for gastric carcinogenesis

William McCormack, Masanobu Oshima, Patrick Tan, Brendan John Jenkins

Research output: Contribution to journalLetterOther

6 Citations (Scopus)

Abstract

Our recent study suggests that at least in the context of gastric cancer, TLR2 antagonists can ameliorate tumour growth by acting directly on the tumour cells to promote apoptosis and suppress proliferation. However, it is important to consider that TLR agonists (including those for TLR2) can induce adaptive immune responses against cancer cells, which supports the application of TLR agonists in cancer vaccine therapy.
Original languageEnglish
Pages (from-to)1260 - 1261
Number of pages2
JournalOncotarget
Volume3
Issue number11
Publication statusPublished - 2012

Cite this

McCormack, W., Oshima, M., Tan, P., & Jenkins, B. J. (2012). Toll-like receptor 2: therapeutic target for gastric carcinogenesis. Oncotarget, 3(11), 1260 - 1261.
McCormack, William ; Oshima, Masanobu ; Tan, Patrick ; Jenkins, Brendan John. / Toll-like receptor 2: therapeutic target for gastric carcinogenesis. In: Oncotarget. 2012 ; Vol. 3, No. 11. pp. 1260 - 1261.
@article{acbd3cbc0d6f4a8ab2bfba7057dc02e8,
title = "Toll-like receptor 2: therapeutic target for gastric carcinogenesis",
abstract = "Our recent study suggests that at least in the context of gastric cancer, TLR2 antagonists can ameliorate tumour growth by acting directly on the tumour cells to promote apoptosis and suppress proliferation. However, it is important to consider that TLR agonists (including those for TLR2) can induce adaptive immune responses against cancer cells, which supports the application of TLR agonists in cancer vaccine therapy.",
author = "William McCormack and Masanobu Oshima and Patrick Tan and Jenkins, {Brendan John}",
year = "2012",
language = "English",
volume = "3",
pages = "1260 -- 1261",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

McCormack, W, Oshima, M, Tan, P & Jenkins, BJ 2012, 'Toll-like receptor 2: therapeutic target for gastric carcinogenesis', Oncotarget, vol. 3, no. 11, pp. 1260 - 1261.

Toll-like receptor 2: therapeutic target for gastric carcinogenesis. / McCormack, William; Oshima, Masanobu; Tan, Patrick; Jenkins, Brendan John.

In: Oncotarget, Vol. 3, No. 11, 2012, p. 1260 - 1261.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Toll-like receptor 2: therapeutic target for gastric carcinogenesis

AU - McCormack, William

AU - Oshima, Masanobu

AU - Tan, Patrick

AU - Jenkins, Brendan John

PY - 2012

Y1 - 2012

N2 - Our recent study suggests that at least in the context of gastric cancer, TLR2 antagonists can ameliorate tumour growth by acting directly on the tumour cells to promote apoptosis and suppress proliferation. However, it is important to consider that TLR agonists (including those for TLR2) can induce adaptive immune responses against cancer cells, which supports the application of TLR agonists in cancer vaccine therapy.

AB - Our recent study suggests that at least in the context of gastric cancer, TLR2 antagonists can ameliorate tumour growth by acting directly on the tumour cells to promote apoptosis and suppress proliferation. However, it is important to consider that TLR agonists (including those for TLR2) can induce adaptive immune responses against cancer cells, which supports the application of TLR agonists in cancer vaccine therapy.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23175464

M3 - Letter

VL - 3

SP - 1260

EP - 1261

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -